Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence

Akira Nomura, Hiroshi Ujike, Yuji Tanaka, Kyohei Otani, Yukitaka Morita, Makiko Kishimoto, Akiko Morio, Mutsuo Harano, Toshiya Inada, Mitsuhiko Yamada, Tokutaro Komiyama, Yoshimoto Sekine, Nakao Iwata, Ichiro Sora, Masaomi Iyo, Norio Ozaki, Shigetoshi Kuroda

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)


Previous studies have indicated that genetic factors substantially affect development of substance use disorders, including methamphetamine dependence. Prodynorphin (PDYN) is an opioid peptide precursor that yields dynorphins, endogenous κ opioid-receptor agonists that play important roles in substance abuse. A physiologically active polymorphism of 1-4 repeats of a 68-bp element in the promoter region of the PDYN gene has been identified. We analyzed this polymorphism of the PDYN gene by a case-control association study in 143 patients with methamphetamine dependence and 209 healthy controls in the Japanese population. A 3- or 4-repeat allele in the PDYN gene promoter was found significantly more frequently in patients with methamphetamine dependence than in controls (χ2 = 9.45, p = 0.0021). A 3- or 4-repeat allele in the PDYN gene promoter, which was shown to produce significantly higher transcription activity of the PDYN gene than a 1- or 2-repeat allele, is a genetic risk factor for development of methamphetamine dependence (odds ratio: 1.83, 95% CI = 1.24-2.68).

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalNeuroscience Letters
Issue number1-2
Publication statusPublished - 29-05-2006

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)


Dive into the research topics of 'Genetic variant of prodynorphin gene is risk factor for methamphetamine dependence'. Together they form a unique fingerprint.

Cite this